Scholar Rock reported its financial results for the second quarter ended June 30, 2025, with a net loss of $110 million, or $0.98 per share. This compares to a net loss of $58.5 million, or $0.60 per share, for the second quarter of 2024.
Research and development expenses increased to $62.4 million in Q2 2025 from $42.373 million in Q2 2024, while general and administrative expenses rose to $49.708 million from $17.125 million. These increases reflect significant investments in advancing the pipeline and building commercial infrastructure.
As of June 30, 2025, cash, cash equivalents, and marketable securities totaled $295.013 million. The company reiterated that its Biologics License Application for apitegromab is progressing under priority review towards the September 22 PDUFA date, and its Marketing Authorisation Application is advancing in the EU.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.